Log in

NASDAQ:ABMDABIOMED Stock Price, Forecast & News

+12.23 (+4.63 %)
(As of 07/15/2020 04:00 PM ET)
Today's Range
Now: $276.64
50-Day Range
MA: $247.16
52-Week Range
Now: $276.64
Volume379,042 shs
Average Volume401,915 shs
Market Capitalization$12.46 billion
P/E Ratio62.59
Dividend YieldN/A
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:ABMD



Sales & Book Value

Annual Sales$840.88 million
Cash Flow$5.52 per share
Book Value$23.64 per share


Net Income$203.01 million


Market Cap$12.46 billion
Next Earnings Date8/6/2020 (Estimated)

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

How has ABIOMED's stock been impacted by COVID-19 (Coronavirus)?

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD stock has increased by 83.0% and is now trading at $276.64. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ABIOMED?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED.

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for ABIOMED.

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings data on Thursday, April, 30th. The medical equipment provider reported $0.70 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.96 by $0.26. The medical equipment provider earned $206.66 million during the quarter, compared to the consensus estimate of $209.58 million. ABIOMED had a return on equity of 18.51% and a net margin of 24.14%. ABIOMED's quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the company posted $1.60 earnings per share. View ABIOMED's earnings history.

What price target have analysts set for ABMD?

9 brokers have issued 12-month target prices for ABIOMED's stock. Their forecasts range from $152.00 to $240.00. On average, they anticipate ABIOMED's share price to reach $193.00 in the next year. This suggests that the stock has a possible downside of 30.2%. View analysts' price targets for ABIOMED.

Has ABIOMED been receiving favorable news coverage?

News articles about ABMD stock have been trending negative on Thursday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ABIOMED earned a news impact score of -2.9 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about ABIOMED.

Are investors shorting ABIOMED?

ABIOMED saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 2,360,000 shares, a decrease of 13.6% from the June 15th total of 2,730,000 shares. Based on an average daily volume of 559,700 shares, the days-to-cover ratio is currently 4.2 days. Currently, 5.4% of the shares of the stock are sold short. View ABIOMED's Current Options Chain.

Who are some of ABIOMED's key competitors?

What other stocks do shareholders of ABIOMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Arista Networks (ANET), Square (SQ), Paypal (PYPL), salesforce.com (CRM) and Adobe (ADBE).

Who are ABIOMED's key executives?

ABIOMED's management team includes the following people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)
  • Dr. David M. Weber, Chief Operating Officer (Age 58)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)
  • Mr. William J. Bolt, Exec. Officer (Age 67)
  • Mr. Ian McLeod, VP & Corp. Controller

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

Who are ABIOMED's major shareholders?

ABIOMED's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.27%), West Coast Financial LLC (0.03%), Envestnet Asset Management Inc. (0.02%), State of Alaska Department of Revenue (0.02%), IFM Investors Pty Ltd (0.01%) and Exchange Traded Concepts LLC (0.01%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter and Michael G Howley. View institutional ownership trends for ABIOMED.

Which institutional investors are selling ABIOMED stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd, and Coe Capital Management LLC. View insider buying and selling activity for ABIOMED.

Which institutional investors are buying ABIOMED stock?

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., West Coast Financial LLC, Legacy Capital Partners Inc., Envestnet Asset Management Inc., Exchange Traded Concepts LLC, Contravisory Investment Management Inc., Cypress Capital Group, and IBM Retirement Fund. View insider buying and selling activity for ABIOMED.

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $276.64.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $12.46 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe.

What is ABIOMED's official website?

The official website for ABIOMED is www.abiomed.com.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.